Get notified when PVLA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- 2,733,437 Options At $14.44 and 2,466,456 Pre-funded Warrants At $0.001 (new) — Large option and warrant overhang well below the offer price creates steep dilution risk for new investors.
Palvella Therapeutics prices $200M primary offering at $125/share; net proceeds $187.3M for QTORIN development
Filed February 26, 2026 · ~1 min read
Key Changes
-
high
Palvella is selling 1,600,000 shares at $125.00 per share, raising $200M gross; net proceeds to the company are $187.3M.
The Offering verify on EDGAR → -
high
Proceeds will fund development of QTORIN rapamycin and QTORIN pitavastatin, plus working capital and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $107.13 per share; pro forma net tangible book value is $17.87 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.
Partner
Trade PVLA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify